EMA’s Committee for Advanced Therapies
The Committee for Advanced Therapies (CAT) is a scientific body of the European Medicines Agency (EMA).
It evaluates advanced therapy medicinal products (ATMPs), including gene, cell, and tissue-based therapies.
Its scientific opinions provide input to the CHMP for the final marketing authorisation decision.
The CAT plays a critical role in assessing the quality, efficacy, and safety of next-generation treatments, supporting innovation in advanced therapies across the European Union.
